TCM
OCUL icon

TCG Crossover Management’s Ocular Therapeutix OCUL Stock Holding History

TCG Crossover Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.2M Hold
1,647,752
– – 0.39% 43
2026
Q1 		$14M Sell
1,647,752
-4,092,479
-71% -$39M 0.4% 39
2025
Q4 		$69.7M Sell
5,740,231
-377,001
-6% -$4.58M 2.31% 12
2025
Q3 		$71.5M Buy
6,117,232
+798,084
+15% +$9.54M 3.52% 7
2025
Q2 		$49.4M Hold
5,319,148
– – 5.64% 4
2025
Q1 		$39M Hold
5,319,148
– – 5.32% 5
2024
Q4 		$45.4M Hold
5,319,148
– – 4.44% 6
2024
Q3 		$46.3M Hold
5,319,148
– – 3.92% 12
2024
Q2 		$36.4M Hold
5,319,148
– – 3.79% 11
2024
Q1 		$48.4M Buy
+5,319,148
New +$37.7M 3.83% 11

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCG Crossover Management's OCUL Position: Q2 2026 in Review

TCG Crossover Management held its Ocular Therapeutix (OCUL) position steady in Q2 2026 at 1,647,752 shares worth $16.2M. The position accounts for 0.39% of the portfolio, ranked #43.

TCG Crossover Management first reported a position in OCUL in Q1 2024 and has held it in 10 quarters since. The position peaked at $71.5M in Q3 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • TCG Crossover Management held 1,647,752 shares of Ocular Therapeutix worth $16.2M as of Q2 2026.
  • TCG Crossover Management left its Ocular Therapeutix share count unchanged in Q2 2026.
  • Ocular Therapeutix made up 0.39% of TCG Crossover Management's portfolio in Q2 2026, its #43 holding.
  • TCG Crossover Management first reported a position in Ocular Therapeutix in Q1 2024 and has held it in 10 quarters since.
  • TCG Crossover Management's Ocular Therapeutix position peaked at $71.5M in Q3 2025.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.